Supernus and Indivior agree merger to create $2.2 billion CNS biopharmaceutical company

The all-stock transaction combines complementary central nervous system portfolios spanning neuroscience and addiction medicine, creating a larger commercial-stage company with a broader product portfolio and pipeline.

Supernus Pharmaceuticals and Indivior have agreed to merge in an all-stock transaction that will create a combined central nervous system (CNS) biopharmaceutical company with approximately $2.2 billion in annual revenue, with Indivior shareholders also receiving a $1 billion special dividend before closing.

The merger brings together complementary commercial portfolios and development pipelines in neuroscience and addiction medicine while aiming to strengthen long-term growth through greater scale and operational efficiencies.

Field	Content
Alert Type	Deal
Companies	Supernus Pharmaceuticals; Indivior Pharmaceuticals
Deal Type	Merger (all-stock transaction)
Asset or Company	Combined CNS biopharmaceutical businesses and product portfolios
Therapy Area(s)	Neuroscience; Psychiatry; Addiction medicine
Deal Value	All-stock merger creating a company with approximately $2.2 billion in annual revenue. Indivior shareholders are expected to receive a $1 billion special dividend before closing. (Reddit)
Geography	Global
What Happened	On 3 August 2026, Supernus Pharmaceuticals and Indivior announced an agreement to merge in an all-stock transaction. Under the terms announced, Supernus shareholders will receive 1.5401 Indivior shares for each Supernus share, while Indivior shareholders will receive a $1 billion special dividend before completion. The combined company will continue to focus on CNS disorders, bringing together commercial products and development programmes across neuroscience and addiction medicine. (Reddit)
Why It Matters	The merger creates a larger CNS-focused pharmaceutical company with a broader commercial portfolio, increased revenue base and a more diversified pipeline. Combining complementary expertise across neurology, psychiatry and addiction medicine could support future product development and commercial execution, although the anticipated benefits will depend on successful integration. (Reddit)
Supporting Context	Supernus has an established portfolio in neurological disorders including ADHD and Parkinson's disease, while Indivior specialises in treatments for opioid use disorder and addiction. The transaction combines businesses with different but complementary CNS therapeutic focuses. (Supernus Pharmaceuticals)
Strategic Rationale	Supernus gains greater commercial scale and access to Indivior's addiction medicine franchise, while Indivior broadens its CNS portfolio through Supernus' neuroscience products and development capabilities. (Reddit)
Potential Impact	If completed, the merger could strengthen the combined company's competitive position within the CNS market through a broader portfolio and increased financial scale. Realisation of these benefits will depend on shareholder approvals, regulatory clearances and successful integration.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com